<?xml version="1.0" encoding="UTF-8"?>
<p>The antiviral activity of hydroxyCQ was demonstrated in vivo by several clinical trials. The somministration of hydroxyCQ was able to reduce the amounts of plasma HIV-1 RNA and IL-6 in patients treated for eight weeks compared to those of the placebo group [
 <xref rid="B39-microorganisms-08-00085" ref-type="bibr">39</xref>]. During a second clinical trial, hydroxyCQ was shown to reduce the HIV-1 RNA plasma level, although at a lower level than the antiviral zidovudine [
 <xref rid="B40-microorganisms-08-00085" ref-type="bibr">40</xref>]. In contrast, the results published in 2012 by Paton and colleagues showed negative results, with an increase in viral load and a decrease in CD4 number [
 <xref rid="B41-microorganisms-08-00085" ref-type="bibr">41</xref>].
</p>
